Introduction

STC-15 METTL3 inhibitor represents a significant advancement in the field of RNA methyltransferase targeting for oncology. STORM Therapeutics Ltd., in collaboration with Evotec, will unveil the discovery of this lead clinical candidate, STC-15, at the American Chemical Society (ACS) Fall 2023 Conference. This presentation underscores the growing importance of RNA modifying enzymes (RMEs) as drug targets and highlights the strategic collaboration between a clinical-stage biotech and a research-driven CDMO partner to co-design and develop novel small molecule therapies. For pharma and CDMO professionals, the STC-15 METTL3 inhibitor exemplifies how integrated drug discovery platforms and targeted enzyme research can accelerate candidate optimization and clinical readiness.

Background on STORM Therapeutics and Evotec

STORM Therapeutics, headquartered in Cambridge, UK, is a clinical-stage biotechnology company focused on discovering and developing therapies that modulate RNA modifying enzymes. Evotec, a Germany-based drug discovery and development CDMO, provides integrated capabilities ranging from target identification to process development and manufacturing. Their partnership leverages STORM’s expertise in RME biology and Evotec’s high-throughput screening, structural biology, and medicinal chemistry platforms. This combination has enabled rapid progression from target validation to lead candidate selection, illustrating the value of specialized alliances in advancing novel modalities.

The STC-15 Discovery and Preclinical Profile

STC-15 is an orally bioavailable, highly selective inhibitor of METTL3, the catalytic subunit of the m6A methyltransferase complex. In preclinical models, STC-15 has demonstrated potent inhibition of RNA methylation, leading to reduced proliferation in METTL3-dependent tumor cell lines and modulation of gene expression profiles associated with oncogenic pathways. Pharmacokinetic studies indicate favorable absorption and distribution properties, with an acceptable safety margin in rodent toxicology assessments. The compound’s selectivity profile minimizes off-target effects on related methyltransferases, positioning STC-15 as a strong candidate for clinical evaluation in hematological and solid tumor indications.

Strategic Collaboration and Co-development

The STORM–Evotec collaboration exemplifies a co-development approach where risk and expertise are shared. Evotec’s state-of-the-art facilities in Toulouse and Hamburg supported iterative medicinal chemistry campaigns, high-throughput screening of analog libraries, and ADME optimization. STORM led the biological characterization and in vitro validation of METTL3 inhibition. Milestone-driven funding facilitated resource alignment and milestone-based decision points, enabling agile project management. This model not only accelerates timelines but also distributes technical risk, a key consideration for pharma and CDMO stakeholders evaluating partnership structures for next-generation targets.

Implications for the Pharma/CDMO Sector

• Novel Target Landscape: The focus on RMEs like METTL3 represents an emerging frontier in epitranscriptomic drug discovery, broadening the scope beyond traditional protein kinases and epigenetic writers.
• Integrated Discovery Platforms: The collaboration highlights how CDMOs with integrated biology-to-process services can de-risk early-stage discovery by maintaining continuity and data integrity across disciplines.
• Strategic Risk Sharing: Co-development agreements with milestone-based payments and shared intellectual property create balanced incentives and can attract investment by demonstrating clear go/no-go criteria.

Presentation at ACS Fall 2023 Conference

At the ACS Fall 2023 Conference, STORM and Evotec will present detailed data on STC-15’s binding kinetics, structure–activity relationships, and in vivo efficacy models. Sessions will cover the design rationale for selectivity against the METTL3 complex, compound optimization strategies, and translational biomarker development to monitor target engagement in clinical settings. For industry attendees, these insights offer a window into best practices for discovering small molecules against complex enzymatic targets and illustrate how partnerships can drive innovation in oncology.

Conclusion

The upcoming ACS presentation of the STC-15 METTL3 inhibitor marks an important milestone for both STORM Therapeutics and Evotec. It underscores the value of targeted RNA methyltransferase inhibitors in oncology and demonstrates the strategic advantages of co-development between biotech innovators and CDMOs. As the field of RME-targeted therapies expands, collaborations like this will serve as models for efficiently translating novel biology into clinical candidates, with significant implications for drug discovery and manufacturing strategies across the pharma and CDMO landscape.